The effectiveness of Colonzak in patients with various clinical variants of irritable bowel syndrome
Keywords:irritable bowel syndrome, treatment, Colonzak, colonoprotector
AbstractBackground. The etiological causes of irritable bowel syndrome (IBS) symptoms have not been fully established. The lack of a clear understanding of the pathogenetic mechanisms of the development of one or another functional intestinal disease, including IBS, taking into account the presence of various structural and morphological disorders in the intestinal wall, dictates the need to search for new drugs, the action of which will be directed to different links in the pathogenesis of intestinal diseases. The aim of the study is to examine the efficacy and safety of Colonzak using in patients with various clinical variants of irritable bowel syndrome. Materials and methods. We examined 42 patients with a verified diagnosis of IBS (14 — IBS type 1; 14 — IBS type 2; 9 — IBS type 3; 5 — IBS type 4) aged 25 to 45 years (average age 35 ± 1.7 years). In all IBS patients, organic intestinal pathology was excluded during colonoscopy. IBS was diagnosed according to Rome IV criteria. In addition to lifestyle modification and adherence to dietary rules, depending on the type of IBS, all patients (regardless of the IBS variant) received monotherapy with Colonzak in a dosage of 1 capsule 2 times a day in the morning and in the evening before meals for 30 days. All patients completed the IBS Symptoms Severity Score (IBS-SSS) questionnaire before and after the study. The results were statistically processed using Excel 2017 (Microsoft) and Statistica 13. Results. The study showed that Colonzak containing probiotic strains of bifidobacteria, prebiotic inulin, and butyric acid can be considered as a safe, well-tolerated, and highly effective drug for the treatment of patients with different types of IBS. In patients with IBS, the use of Colonzak was accompanied by a statistically significant increase in the clinical effectiveness of treatment. Conclusions. Our study has confirmed the clinical efficacy of Colonzak as a multicomponent protector for a colon in IBS. The results obtained allow us to recommend the widespread use of Сolonzak in the complex treatment of patients with different types of IBS.
Aziz I, Törnblom H, Palsson OS, Whitehead WE, Simrén M. How the Change in IBS Criteria From Rome III to Rome IV Impacts on Clinical Characteristics and Key Pathophysiological Factors. Am J Gastroenterol. 2018 Jul;113(7):1017-1025. doi:10.1038/s41395-018-0074-z.
Vork L, Weerts ZZRM, Mujagic Z, et al. Rome III vs Rome IV criteria for irritable bowel syndrome: A comparison of clinical characteristics in a large cohort study. Neurogastroenterol Motil. 2018 Feb;30(2). doi:10.1111/nmo.13189.
Cañón M, Ruiz AJ, Rondón M, Alvarado J. Prevalence of irritable bowel syndrome and health-related quality of life in adults aged 18 to 30 years in a Colombian University: an electronic survey. Ann Gastroenterol. 2017;30(1):67-75. doi:10.20524/aog.2016.0093.
Wu JC, Chan AO, Chan YW, Cheung GC, Cheung TK, Kwan AC, Leung VK, Mak AD, Sze WC, Wong R. The current treatment landscape of irritable bowel syndrome in adults in Hong Kong: consensus statements. Hong Kong Med J. 2017 Dec;23(6):641-647. doi:10.12809/hkmj177060.
Klem F, Wadhwa A, Prokop LJ, et al. Prevalence, Risk Factors, and Outcomes of Irritable Bowel Syndrome After Infectious Enteritis: A Systematic Review and Meta-analysis. Gastroenterology. 2017 Apr;152(5):1042-1054.e1. doi:10.1053/j.gastro.2016.12.039.
Wong RK, Yang C, Song GH, Wong J, Ho KY. Melatonin regulation as a possible mechanism for probiotic (VSL#3) in irritable bowel syndrome: a randomized double-blinded placebo study. Dig Dis Sci. 2015 Jan;60(1):186-194. doi:10.1007/s10620-014-3299-8.
Yoon H, Park YS, Lee DH, Seo JG, Shin CM, Kim N. Effect of administering a multi-species probiotic mixture on the changes in fecal microbiota and symptoms of irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J Clin Biochem Nutr. 2015 Sep;57(2):129-134. doi:10.3164/jcbn.15-14.
Chen B, Kim JJ, Zhang Y, Du L, Dai N. Prevalence and predictors of small intestinal bacterial overgrowth in irritable bowel syndrome: a systematic review and meta-analysis. J Gastroenterol. 2018 Jul;53(7):807-818. doi:10.1007/s00535-018-1476-9.
Copyright (c) 2020 GASTROENTEROLOGY
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our edition uses the copyright terms of Creative Commons for open access journals.
Authors, who are published in this journal, agree with the following terms:
- The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
- Directing the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
- The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
- The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
- The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
- The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
- The rights to the article are deemed transferred by the authors to the edition (the publisher) since the moment of the publication of the article in the printed or electronic version of journal.